Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/26/2008


Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET)

2007 Financial Highlights

- Total BioMarin revenue of $121.6 million

- Naglazyme net product revenue of $86.2 million, an increase of 85.4

percent over 2006 and above BioMarin's guidance range of $82 million

to $84 million

- Aldurazyme net product revenue of $123.7 million, an increase of 28.5

percent over 2006 and toward the upper end of BioMarin's guidance

range of $115 million to $125 million

- Net loss of $15.8 million, within the guidance range of a loss of $13

million to $18 million

- Net income of $2.6 million in the fourth quarter of 2007

2008 Financial Guidance

- Total BioMarin revenue in the range of $255 million to $306 million

which includes total product revenue of $213 million to $264 million

- Naglazyme net product revenue in the range of $105 million to $116

million

- Aldurazyme net product sales by Genzyme of $135 million to $145

million with net revenue to BioMarin from royalties and transfers of

inventory in the range of $68 million to $78 million

- Improved Kuvan net product revenue guidance in the range of $40

million to $70 million

- GAAP net income in the range of $20 million to $40 million and

non-GAAP net income in the range of $47 million to $67 million

NOVATO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2007. Net income was $2.6 million ($0.03 per share) for the fourth quarter of 2007, compared to a net loss of $10.4 million ($0.11 per share) for the fourth quarter of 2006. Net income for the fourth quarter of 2007 includes the receipt of the $15.0 million milestone payment from Merck Serono related to
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
(Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... N.C., Dec. 8, 2010 Pharmaceutical Institute, ... pharmaceutical and biotech industry and a subsidiary of Campbell ... Hospital Marketplace e-course series.  It ... and Institutional IT Systems ...
... 8, 2010 Reportlinker.com announces that a new ... Merck KGaA: PharmaVitae Profile ... IntroductionThis analysis examines the historical and forecast ... sector. The profile encompasses global company strategy, portfolio ...
... 8, 2010 Aquatic Energy LLC announced today that ... Zulandi, have joined its Board of Directors.  "Our new ... experience to our company," stated David Johnston, CEO of ... time, as the company moves from proof-of-concept demonstration facilities ...
Cached Biology Technology:Hospital Marketplace E-Course Suite Adds Insight on Quality and Information Systems 2Reportlinker Adds Merck KGaA: PharmaVitae Profile 2Senior Energy Executives Join Aquatic Energy Board 2Senior Energy Executives Join Aquatic Energy Board 3
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today ... the University of Massachusetts Amherst School of Public ... three-year, $700,000 Science to Achieve Results (STAR) grant ... by Native subsistence hunters in subarctic North America ... exposure and to provide culturally-relevant recommendations for mitigation. ...
(Date:7/23/2014)... fable about the crow and the pitcher, a thirsty bird ... to drink from it, he finds the water level out ... pitcher, the bird drops pebbles into it one at ... him to drink his fill. , Highlighting the value of ... more effective than brute force. It also characterizes crows as ...
(Date:7/23/2014)... Defense recently awarded the STEMPREP Project at Southern ... its goal of increasing the number of minorities ... middle school students for the two-summer classroom phase ... students with summer opportunities at research labs. , ... School of Education and Human Development, boasts an ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
... are common, but few studies of lung nodule identification ... Researchers from Kaiser Permanente Southern California identified 7,112 patients ... information within the electronic medical record. Their ... International Association for the Study of Lung Cancer,s (IASLC) ...
... Your genes determine much about you, but environment can ... with consequences that can last a lifetime. In a ... ), researchers have for the first time shown that the ... the chemical modifications to DNA we are born with, that ...
... some cases of the progressive fatal neurological disease amyotrophic ... disease. Shedding light on how ALS destroys the cells ... in this gene affect the structure and growth of ... cells responsible for controlling muscles. People with ALS experience ...
Cached Biology News:Differences between human twins at birth highlight importance of intrauterine environment 2New gene mutations linked to ALS and nerve cell growth dysfunction 2New gene mutations linked to ALS and nerve cell growth dysfunction 3
... enterprise microarray informatics platform for microarray data storage, ... and use it forever without paying ongoing license ... Acuity has all the analysis tools you need ... quality control statistics and normalization, all the way ...
... industry standard microarray image analysis software because ... analysis tools, visualizations, automation capabilities, performance and ... with every GenePix scanner, and it also ... all types of arrays. A wide range ...
A univariate (peak height or area) quantitative multi-component analysis package....
... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
Biology Products: